S.BIOMEDICS reports positive data from Parkinson’s trial of TED-A9 cell therapy

S.BIOMEDICS has shared encouraging results from a study testing its new cell therapy, TED-A9, for Parkinson’s disease. After one year, participants showed significant improvements, suggesting the therapy could be effective. The trial included 12 people aged 50 to 75 who had Parkinson’s for over five years and were struggling with movement issues. Researchers tracked progress using tools to measure disease severity and motor skills. In the group receiving a lower dose of the therapy, symptoms improved by about 19%. Those on a higher dose improved by 44%, with some moving from severe to milder stages of the disease. A key symptom, freezing of gait, completely disappeared for all in the high-dose group and for one person in the low-dose group. Brain scans showed the therapy helped restore dopamine, a brain chemical affected by Parkinson’s, by increasing dopamine transporters. This means the transplanted cells successfully formed new connections in the brain. Non-motor symptoms, such as mood and daily activities, also improved. Importantly, no serious side effects related to the treatment were reported. Only one mild bleeding incident occurred, and it was unrelated to the therapy. S.BIOMEDICS' chief technology officer, Dong-Wook Kim, said the results show that TED-A9 not only helps improve symptoms but also works in the way scientists hoped. The study is ongoing, and more findings will be shared in the future.